266
Views
7
CrossRef citations to date
0
Altmetric
Report

Rituximab therapy for patients with Langerhans cell histiocytosis-associated neurologic dysfunction

, , , , , , & show all
Pages 427-433 | Received 22 Aug 2018, Accepted 07 Nov 2018, Published online: 31 Dec 2018
 

Abstract

Objective: Since patients with langerhans cell histiocytosis and neurologic dysfunction (LCH–ND) often have incomplete treatment responses we sought a new treatment regimen. Because of clinical benefit from rituximab in multiple sclerosis patients with neurodegeneration, we evaluated its use in patients with LCH–ND. Participants: Eight LCH–ND patients who had failed prior therapies. Methods: Charts of the 8 patients treated with rituximab were reviewed. Signs/symptoms and MRI responses were assessed. Results: Seven of eight patients experienced some clinical improvement: gait abnormalities and tremors in four children, proprioceptive deficits in 2, and dysarthria/dysphagia in 2. Five of eight patients demonstrated improvement in intellectual/behavioral/psychological symptoms. Conclusion: These findings suggest that prospective studies are warranted to define safety and efficacy of rituximab for patients with LCH–ND.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.